Managers / Q4 2019 · view latest →
Sivik Global Healthcare LLC
CIK 0001596452 · 133 TACONIC RD, GREENWICH, CT, 06831 · 203-769-8600
Reported Value
$269M
Q4 2019
Positions
50
Filings on Record
30
2019–present window
Filed
Feb 13, 2020
original filing
Summary
Sivik Global Healthcare LLC reported $269M in U.S.-listed holdings across 50 positions for Q4 2019.
Its largest position, HUM, represents 3.7% of the portfolio.
Compared with Q3 2019, the fund opened 13 new positions and exited 7.
Portfolio Metrics
Turnover
+14.2%
vs prior filed quarter
Top-10 Concentration
+31.4%
share of reported value
Largest Position
+3.7%
Humana
New / Exited
13 / 7
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 89.3% · $241M
- ADR · 8.8% · $24M
- Other · 1.6% · $4M
- ETP · 0.3% · $825,000
Quarter-over-Quarter Changes full breakdown →
vs Q3 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| BMYBristol-Myers Squibb Co | NEW | +130.0K | 130.0K | +$8M | $8M |
| AMGNAmgen Inc | NEW | +25.0K | 25.0K | +$6M | $6M |
| BIIBBiogen Inc | NEW | +20.0K | 20.0K | +$6M | $6M |
| ZBHZimmer Biomet Holdings Inc | NEW | +35.0K | 35.0K | +$5M | $5M |
| JNJJohnson & Johnson | NEW | +35.0K | 35.0K | +$5M | $5M |
| ABBVAbbVie Inc | NEW | +50.0K | 50.0K | +$4M | $4M |
| ALGNAlign Technology Inc | NEW | +15.0K | 15.0K | +$4M | $4M |
| SNNSmith & Nephew PLC | NEW | +75.0K | 75.0K | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2019
49 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | HUMHumana Inchistory → | Cash Securities | 3.74% | $10M | 27.5K |
| 2 | HCAHCA Healthcare Inchistory → | Cash Securities | 3.43% | $9M | 62.5K |
| 3 | CNCCentene Corphistory → | Cash Securities | 3.15% | $8M | 135.0K |
| 4 | BMYBristol-Myers Squibb Cohistory → | Cash Securities | 3.10% | $8M | 130.0K |
| 5 | ELVAnthem Inchistory → | Cash Securities | 3.08% | $8M | 27.5K |
| 6 | CICigna Corphistory → | Cash Securities | 3.04% | $8M | 40.0K |
| 7 | THCTenet Healthcare Corphistory → | Cash Securities | 3.03% | $8M | 215.0K |
| 8 | UNHUnitedHealth Group Inchistory → | Cash Securities | 3.00% | $8M | 27.5K |
| 9 | BSXBoston Scientific Corphistory → | Cash Securities | 2.94% | $8M | 175.0K |
| 10 | UHSUniversal Health Services Inchistory → | Cash Securities | 2.93% | $8M | 55.0K |
| 11 | DHRDanaher Corphistory → | Cash Securities | 2.85% | $8M | 50.0K |
| 12 | SNYSanofi ADRhistory → | Cash Securities | 2.80% | $8M | 150.0K |
| 13 | REGNRegeneron Pharmaceuticals Inchistory → | Cash Securities | 2.79% | $8M | 20.0K |
| 14 | ISRGIntuitive Surgical Inchistory → | Cash Securities | 2.74% | $7M | 12.5K |
| 15 | VRTXVertex Pharmaceuticals Inchistory → | Cash Securities | 2.64% | $7M | 32.5K |
| 16 | MRKMerck & Co Inchistory → | Cash Securities | 2.53% | $7M | 75.0K |
| 17 | BMRNBioMarin Pharmaceutical Inchistory → | Cash Securities | 2.51% | $7M | 80.0K |
| 18 | LLYEli Lilly & Cohistory → | Cash Securities | 2.44% | $7M | 50.0K |
| 19 | GRFSGrifols SA ADRhistory → | Cash Securities | 2.38% | $6M | 275.0K |
| 20 | AZNNAstraZeneca PLC ADRhistory → | Cash Securities | 2.31% | $6M | 125.0K |
| 21 | AMGNAmgen Inchistory → | Cash Securities | 2.24% | $6M | 25.0K |
| 22 | BIIBBiogen Inchistory → | Cash Securities | 2.20% | $6M | 20.0K |
| 23 | BAXBaxter International Inchistory → | Cash Securities | 2.17% | $6M | 70.0K |
| 24 | TMOThermo Fisher Scientific Inchistory → | Cash Securities | 2.11% | $6M | 17.5K |
| 25 | BIOBio-Rad Laboratories Inchistory → | Cash Securities | 2.06% | $6M | 15.0K |
| 26 | IQVIQVIA Holdings Inchistory → | Cash Securities | 2.01% | $5M | 35.0K |
| 27 | ZTSZoetis Inchistory → | Cash Securities | 1.97% | $5M | 40.0K |
| 28 | SYKStryker Corphistory → | Cash Securities | 1.95% | $5M | 25.0K |
| 29 | ZBHZimmer Biomet Holdings Inchistory → | Cash Securities | 1.94% | $5M | 35.0K |
| 30 | ABTAbbott Laboratorieshistory → | Cash Securities | 1.93% | $5M | 60.0K |
| 31 | MDTMedtronic PLChistory → | Cash Securities | 1.89% | $5M | 45.0K |
| 32 | JNJJohnson & Johnsonhistory → | Cash Securities | 1.89% | $5M | 35.0K |
| 33 | ABBVAbbVie Inchistory → | Cash Securities | 1.64% | $4M | 50.0K |
| 34 | Laboratory Corp of America Ho | Cash Securities | 1.57% | $4M | 25.0K |
| 35 | ALGNAlign Technology Inchistory → | Cash Securities | 1.55% | $4M | 15.0K |
| 36 | SNNSmith & Nephew PLChistory → | Cash Securities | 1.34% | $4M | 75.0K |
| 37 | EWEdwards Lifesciences Corphistory → | Cash Securities | 1.30% | $3M | 15.0K |
| 38 | INCYIncyte Corphistory → | Cash Securities | 1.30% | $3M | 40.0K |
| 39 | ILMNIllumina Inchistory → | Cash Securities | 1.23% | $3M | 10.0K |
| 40 | DGXQuest Diagnostics Inchistory → | Cash Securities | 1.09% | $3M | 27.5K |
| 41 | SRPTSarepta Therapeutics Inchistory → | Cash Securities | 1.08% | $3M | 22.5K |
| 42 | AVTRAvantor Inchistory → | Cash Securities | 1.01% | $3M | 150.0K |
| 43 | ALCAlcon Inc | Cash Securities | 0.95% | $3M | 45.0K |
| 44 | HRCHill-Rom Holdings Inc | Cash Securities | 0.84% | $2M | 19.9K |
| 45 | Seattle Genetics Inc | Cash Securities | 0.83% | $2M | 19.5K |
| 46 | Bluebird Bio Inc | Cash Securities | 0.65% | $2M | 20.0K |
| 47 | CRSPCRISPR Therapeutics AG | Cash Securities | 0.57% | $2M | 25.0K |
| 48 | Blueprint Medicines Corp | Cash Securities | 0.55% | $1M | 18.5K |
| 49 | Sage Therapeutics Inc | Cash Securities | 0.40% | $1M | 15.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $132M | 34 | Apr 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $345M | 49 | Jan 21, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $344M | 44 | Oct 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $368M | 46 | Jul 25, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $185M | 31 | Apr 22, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $190M | 38 | Jan 23, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $236M | 35 | Nov 6, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $278M | 38 | Jul 29, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $427M | 47 | May 1, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $239M | 39 | Feb 5, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $198M | 33 | Nov 7, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $428M | 43 | Aug 9, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $233M | 40 | May 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $213M | 39 | Feb 8, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $180M | 41 | Nov 4, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $176M | 38 | Aug 10, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $242M | 49 | May 9, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $233M | 45 | Feb 8, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $419M | 43 | Nov 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $512M | 49 | Aug 10, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $274M | 47 | May 12, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $245M | 38 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $232M | 38 | Nov 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $302M | 52 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $253M | 40 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $269M | 50 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $198M | 45 | Nov 12, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $414M | 62 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $271M | 61 | May 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $186M | 48 | Feb 12, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.